Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 793 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skull Clear all
Completed Phase 2 Interventional

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

NCT00021333
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT04201262
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 28, 2026, 1:51 PM EDT
Completed No phase listed Observational

Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study

NCT01212731
View directory record Official record
Conditions
Malignancy, Glioma, Radiotherapy
Interventions
Photon treatment plans, Proton Treatment Plans, Neurocognitive evaluation, Advanced MRI imaging
Radiation · Behavioral · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 28, 2026, 1:51 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

NCT03913143
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Sham
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
8 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Not applicable Interventional

Auditory Nerve Test System During Vestibular Schwannoma Resection

NCT04241679
View directory record Official record
Conditions
Vestibular Schwannoma, Acoustic Neuroma, Sensorineural Hearing Loss, Asymmetric Sensorineural Hearing Loss, Cochlear Nerve Damage, Cochlear Nerve Deafness, Skull Base Neoplasms, Auditory; Nerve
Interventions
Auditory Nerve Test System
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Not applicable Interventional

Persistent Post-Concussion Symptoms With Convergence Insufficiency

NCT05262361
View directory record Official record
Conditions
Persistent Post-concussive Symptoms, Convergence Insufficiency, Mild Traumatic Brain Injury, Concussion, Mild, Concussion; Eye
Interventions
Office-based Vergence and Accommodative Therapy
Behavioral
Lead sponsor
New Jersey Institute of Technology
Other
Eligibility
11 Years to 35 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Newark, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

NCT07863180
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
Interventions
Tributyrin, Placebo
Drug
Lead sponsor
Prabesh Kanel
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT05199688
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions
Satralizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 11 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

NCT04743310
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
tozuleristide, Canvas imaging system, Surgical resection of tumor
Drug · Device · Procedure
Lead sponsor
John Yu
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Completed No phase listed Observational

Does LMA Instead of ET Tube Affect Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction?

NCT00338559
View directory record Official record
Conditions
Strabismus
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 12 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau Imaging With JNJ067

NCT03926702
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
Interventions
Radiopharmaceuticals
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 28, 2026, 1:51 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Maintaining Cochlear Patency After VIIIth Nerve Surgery

NCT03261726
View directory record Official record
Conditions
Acoustic Neuroma, Labyrinthitis Ossificans, Profound Hearing Impairment
Interventions
MedEl Test Electrode Placer
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cranial Electrotherapy Stimulation: Piloting a Road to PTSD Prevention in First Responders

NCT06203717
View directory record Official record
Conditions
Adults, Firefighters
Interventions
Alpha-Stim AID cranial electrotherapy stimulation
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 56 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Stryker Hybrid Arch Bars

NCT02283528
View directory record Official record
Conditions
Fracture Mandible
Interventions
Stryker Hybrid, Erich
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 28, 2026, 1:51 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

NCT03446807
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Droxidopa, Placebo Oral Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 28, 2026, 1:51 PM EDT
Not listed Not applicable Interventional

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

NCT01586767
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Squamous Cell Carcinoma, Sinonasal Carcinoma, Sinonasal Undifferentiated Carcinoma, Mucoepidermoid Carcinoma, Schneiderian Carcinoma, Myoepithelial Carcinoma, Esthesioneuroblastoma, Melanoma
Interventions
Proton radiation therapy, Intensity-modulated radiotherapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 28, 2026, 1:51 PM EDT
Terminated Phase 4 Interventional Results available

Cranial Blocks for Postoperative Anesthesia

NCT04749797
View directory record Official record
Conditions
Craniotomy Surgery
Interventions
Liposomal bupivacaine, Bupivacaine Injection, Saline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 28, 2026, 1:51 PM EDT
Active, not recruiting No phase listed Observational

Stryker Facial iD Universal Plate Configurator: A Retrospective Post Market Follow Up

NCT07245810
View directory record Official record
Conditions
Mandibular Fractures, Facial Fracture, Maxilla Fracture, Orthognathic Surgical Procedures
Interventions
Orthognatic surgery, Reconstructive maxillofacial surgery, Mandible and maxillofacial trauma surgery
Device
Lead sponsor
Stryker Craniomaxillofacial
Industry
Eligibility
Not listed
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Not listed Phase 2Phase 3 Interventional

Bupivacaine Injection of Eye Muscles to Treat Strabismus

NCT01616108
View directory record Official record
Conditions
Strabismus, Esotropia, Exotropia, Graves Disease, Ptosis, Eyelid
Interventions
Bupivacaine
Drug
Lead sponsor
Smith-Kettlewell Eye Research Institute
Other
Eligibility
8 Years to 95 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Phase 4 Interventional

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT01975324
View directory record Official record
Conditions
Non Arteritic Ischemic Optic Neuropathy
Interventions
dalfampridine, Placebo
Drug
Lead sponsor
Neuro-Ophthalmologic Associates, PC
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

Cranial Electrotherapy Stimulation in Burned Patients

NCT00723008
View directory record Official record
Conditions
Post Traumatic Stress Disorders, Burns
Interventions
Alpha Stim 100 (Cranial Electrotherapy Stimulation)
Device
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 28, 2026, 1:51 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT07453888
View directory record Official record
Conditions
Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
50 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 1:51 PM EDT
Completed Not applicable Interventional Results available

Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery

NCT01812044
View directory record Official record
Conditions
Strabismus
Interventions
subtenons anesthetic - preservative-free bupivacaine 0.75%, topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel, topical control - 0.5 cc of Hypromellose 0.3% gel, subtenons control - 0.5 cc of Normal Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
1 Year to 7 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 28, 2026, 1:51 PM EDT
Recruiting Phase 2 Interventional

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311
View directory record Official record
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 1:51 PM EDT